Relative Potency of Percutaneously Absorbed Corticosteroids in the Suppression of Pituitary-Adrenal Function**From the Departments of Dermatology and Medicine of the Harvard Medical School and the Dermatology and Medical (Endocrine Unit) Services of the Massachusetts General Hospital, Boston, Massachusetts.  by Scoggins, Robert B. & Kliman, Bernard
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Copyright 1965 by The Williams & Wilkins Co.
Vol. 45, No. 5
Printed in U.S.A.
RELATIVE POTENCY OF PERCUTANEOUSLY ABSORBED
CORTICOSTEROIDS IN THE SUPPRESSION OF
PITUITARY-ADRENAL FUNCTION*
ROBERT B. SCOGGINS, M.D.55t AND BERNARD KLTMAN, M.D.*s*
We have previously shown that corticoster-
oids, when applied to diseased skin under an
occlusive dressing, may be absorbed through
the skin in quantities sufficient to cause sys-
temic response (1, 2). Similar findings have
been reported by several other investigators (3,
4, 5, 6). Suppression of pituitary-adrenal func-
tion, as indicated by decreases in plasma cor-
tisol and urinary steroid levels, has appeared
to be the most sensitive indicator of the sys-
temic pharmacologic activity of synthetic cor-
ticosteroids.
In the studies reported here, suppression is
used as an end-point to determine dose-re-
sponse relationships and potency differences
among topical corticosteroid preparations ap-
plied with occlusion. In particular, we have
attempted to evaluate the relative suppression
potencies of four compounds that showed evi-
dence in animal studies of significant anti-in-
flammatory activity with a lesser degree of
other glucocorticoid effects than currently
employed drugs. The structural formulae of
these compounds are shown in Fig. 1. Dichlori-
sone acetate has been available for clinical use;
the others remain under investigation. All ex-
cept the 9, 1 1-dichloro analog of triamcinolone
acetonide demonstrate less suppressing potency
than the drugs with which they were compared:
triamcinolone acetonide, fluocinolone acetonide,
flurandrenolone, and prednisolone.
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MATERIALS AND METHOn5
Patients
Sixteen studies were performed on four male
patients hospitalized in a metabolic study unit.
Three patients had psoriasis, one had atopic
dermatitis. Evidence of impaired epidermal barrier
function in the diseased skin was demonstrated by
skin electrical resistance measurements' and medi-
cation was applied only to diseased skin. None of
the patients had co-existing disease, and none had
received recent corticosteroid therapy.
Procedures and Medications
In each study, a treatment period was pre-
ceded and followed by an appropriate control
period. Each "day" of study was a 24-hour period
terminating at 8:00 am., when treatment and
urine collections were ended and blood was ob-
tained.
Medications other than the drug being tested
and diphenhydramine hydrochloride were pro-
hibited. Petrolatum was applied, when needed, to
untreated areas, and cottonseed oil and prepara-
tions containing hexachlorophene were allowed in
the bath.
In addition to the drugs listed in Fig. 1, the
following were studied: prednisolone (delta-i
hydrocortisone); triamcinolone acetonide (9a-
fluoro - i6a - hydroxy - prednisolone - 16,17 -
acetonide); flurandrenolone (Ba - fluoro - i6a -
hydroxy - hydrocortisone - 16,17 - acetonide);
fluocinolone acetonide (6a - fluorotrinmcinolone -
16, 17-acetonide). All drugs studied were applied
in commercial cream vehicles in concentrations
described below. Amounts to be applied were
weighed separately for each application, applied
evenly to the designated areas, massaged into the
skin as thoroughly as possible, and covered with
an occlusive plastic dressing. Except in the stud-
ies of patient R.R., all applications were made to
approximately 20% of body surface and fresh
sites of application were used with each change
of dose or drug. Applications were made twice
daily, at 9:00 a.m. and 7:00 p.m. Medication and
dressing were left in place continuously except
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Fio. 2. Effects of 0.3% tetrahydro-triamcinolone
acetonide (THTA) cream applied at two dose
levels: I 30 gm bi.d. (180 mg THTA/24 hrs); II
60 gin b.i.d. (360mg THTA/24 hrs.).
for the hour preceding each application, when the
patient bathed.
Laboratory Determinations
Urine was collected during 24-hour periods, and
stored at 4°C during collection without the addi-
tion of preservatives. Sodium and potassium con-
tent were measured by flame-photometry. Creati-
nine excretion was determined daily during all
studies, and revealed no gross inaccuracy of urine
collection or changes of renal function at any
time. Aliquots for steroid determinations were
frozen. 17-Hydroxycorticosteroid content (17-
OHCS) was determined after glucuronidase hy-
drolysis by a modification of the Porter-Silber
technique (7); 17-ketosteroid content (17-KS)
was determined after acid hydrolysis by the
method of Vestergaard (8); and 17-ketogenic-
steroid content (17-KGS) by the method of
Norymberski (0, 10)2. Normal values for the age
groups studied are: 17-OHCS, 3.5—8 mg/24 hrs.;
17-KS, 8—26 mg/24 hrs.; 17-KGS, 8—18 mg/24 hrs.
Blood was obtained while the patient was fast-
ing. Eosinophil counts were made on blood col-
lected in versenated tubes and are reported as
the average of duplicate counts. With the excep-
tion of plasma cortisol, all determinations were
made by standard methods in the clinical labora-
tory of the hospital. Plasma cortisol (hydrocorti-
sone, compound F) concentration was determined
by the double-isotope derivative method of
Kliman and Peterson (11). Normal early morning
values are 5—25 mcg/l00 ml.
Periods of treatment with the drugs under in-
2 Done by Dr. Maurice M. Pechet.
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vestigation were preceded and followed by deter-
minations of hemogram, liver function, crentinine
clearance, and fasting and post-prandial blood
sugar. No significant changes attributable to the
drugs were found.
RESULTS
Patient ft. ft. was a 23 year old man with
generalized psoriasis. His diet during the study
contained 149 meq. of sodium and 90 meq. of
potassium daily, and fluid intake was 3000
ml/24 hours. As shown in Fig. 2, pituitary ad-
renal function, as indicated by decreases in
plasma cortisol and urinary steroid levels, was
suppressed when 0.3% tetrahydro-triamcinolonc
acetonide (THTA) was applied at two dose
levels to 90% of body surface. Further evi-
dences of systemic activity of the drug were
the following changes in average treatment-
period values from average control values: a
decrease in cosinophil counts of 45% during the
first treatment period and 57% during the sec-
ond; an increase in urinary potassium excretion
of 43% during the second period, with no
change during the first; an increase in uriuary
sodium excretion of 23% during the first and
32% during the second period; an increase in
total urine volume of 80% during both treat-
ment periods.
Patient F. B. was a 23 year old man with
generalized atopic dermatitis. To attempt to
obtain a dose-response relationship, 0.01%
fluocinolone acetonide was applied to 20% of
body surface in increasing doses (Fig. 3), the
dose being increased and site of application
rotated at two-day intervals, establishing the
procedure for the remainder of the studies re-
ported here. Ten grams of that preparation
applied twice daily caused no changes. Twenty
grams applied similarly suppressed pituitary-
adrenal function as shown by lowered urinary
17-OHCS and plasma cortisol levels, and a
moderate lowering of the circulating eosinopbil
count. At the higher dose levels, suppression
continued and the eosinophil count decreased
further.
When 20% and 90% of body surface which
had recently been treated were occluded with a
vehicle alone as a control procedure, no fall in
steroid level or eosinophil count occurred (Fig.
3). In fact, steroid values increased when the
larger surface area was occluded, perhaps re-
flecting the stress of increased body tempera-
ture and the discomfort induced by this pro-
cedure.
It was not possible to obtain a dose-response
curve with 0.05% fiurandrenolone, because the
smallest dose selected (5 gm twice daily) caused
complete suppression (Fig. 4).
Because data from other sources (12) indi-
cated that THTA retained anti-inflammatory
activity at lower concentrations than were em-
ployed in the study of patient R.R., further
studies of the potency of this drug were made
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Fm. 3. Effects of 0.01% fluocinolonc acctonidc (FA) cream: 1 10 gm bid. (2 mg FA/24
hrs.); 11 20 gm bi.d. (4 mg FA/24 hrs.); III 30 gm bid. (6 mg FA/24 hrs.); IV 40 gm bid.(8 mg FA/24 hrs.). Effects of occlusion without medication over 20% (I) and 90% (II) of
body surface.
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FJG. 4. Effects of 0.05% flurandrenolone (Fl) cream: I 5 gm bid. (5 mg F1/24 hrs.); II
10 gm bid. (10 mg F1/24 hrs.); III 15 gm bid. (15 mg F1/24 hrs.). Effects of 0.05% tetra-
hydro-triamcinolone acetonide (THTA) cream: I 30 gm bid. (30 mg TIITA/24 hrs.); II
45 gm b.i.d. (45 mg TIITA/24 hrs.); III 60 gm bi.d. (60 mg TIITA/24 hrs.). Effects of 0.5%
predniso)one (P) cream: I 5 gm bi.d. (50 mg P124 hrs.); II 10 gm bid. (100 mg P124 hrs.).
PLASMA
CORIISOL
(jig / 100 ml)
URINARY
17—OH CS
(mg / 24 Hr.
URINARY
17 —KGS
(mg / 24 Hr.)
DAY
Fm. 5. Effects of 0.05% tetrahydro-triamcinolone acetonide (THTA) cream: 1 15 gm bi.d.(15mg THTA/24 hrs.); 1130 gm bi.d. (30 mg TIITA/24 hrs.); 111 45 gm b.i.d. (45 mg
TIITA/24 hrs.); IV 90 gm b.i.d. (90 mg THTA/24 hrs.). Effects of 0.025% triamcinolone
acetonide (TA) cream: 1 15 gm bi.d. (7.5 mg TA/24 hrs.); 11 5 gm bi.d. (2.5 mg TA/24
hrs.); III 10 gm bi.d. (5 mg TA/24 hrs.).
with a concentration of 0.05% (Fig. 4). None
of the dose levels employed suppressed func-
tion.
As with flurandrenolone, a dose-response
curve was not obtained with 0.5% prednisolone,
because the smallest dose studied caused com-
plete suppression (Fig. 4). This indicated also
that the epidermal harrier remained damaged.
The failure of THTA to cause suppression was,
therefore, not attributable to healing of the
skin with reformation of the harrier.
Patient RH. was a 23 year old man with
exfoliative psoriasis. As seen in Fig. 5, the three
lower dose levels of 0.05% THTA produced no
bid
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5
0
8
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evidence of suppression except for the low
plasma cortisol level after the second day of
application of 45 gm twice daily. Urinary ster-
oid levels did not decrease markedly until 90
gm were applied twice daily. One would antici-
pate further decreases if that dose were applied
for more than one day.
Fifteen grams twice daily of 0.025% triam-
cinolone acetonide (TA) caused suppression.
To obtain a better comparison of the relative
suppression potencies of TA and THTA, lower
doses of TA were studied. Five grams twice
daily had no effect, and ten grams twice daily
appeared to cause minimal suppression of pitu-
itary-adrenal function. These findings correlate
well with those in the subsequent study of
patient J.V.C., in whom S gm of 0.025% TA did
not, but 16 gm twice daily did cause suppres-
sion.
Three other studies of this patient during
the same hospitalization should be mentioned.
In the first, occlusion of 40% of body surface
with a vehicle only, a control procedure, caused
no change in urinary 17-OHCS or plasma cor-
tisol levels. In another, 0.025% TA was applied
once daily at 7:00 p.m. and allowed to remain
until the following 8:00 a.m. Fifteen grams
were sufficient to decrease plasma cortisol by
the end of the application period, but insuffi-
cient to lower urinary 17-OHCS except mini-
mally in a 24-hour specimen. Thirty and forty-
five grams, however, were sufficient to decrease
both urinary and plasma steroids to suppres-
sion levels. In the final study, 20 gm of 0.25%
dichiorisonc acetate applied twice daily (100
mg of dichlorisone acetate/24 hours) did not
decrease cndogenous cortisol production.
Patient J.V.C. was a 45 year old man with
generalized psoriasis. As shown in Fig. 6, none
of the amounts of 0.01% TA or 1.0% 21-deoxy-
triamcinolonc acetonidc applied produced sup-
pression, whereas the smallest amount of 1.0%
of the 9, 11-dichloro analog of TA did so, as
also did larger amounts not shown in the figure.
When placebo cream was applied, no remark-
able changes in laboratory findings ensued (Fig.
7). The three doses levels of 0.25% dichlorisonc
acetate studied failed to cause suppression.
To study the effect of concentration of a
steroid in its vehicle upon its absorption
through the skin, the systemic effects of 0.025%
TA were compared with those of the previously
applied 0.01% concentration. Two, four and
eight milligrams of TA/24 hrs. in 0.01% con-
centration had not caused suppression. Four
milligrams of TA/24 hrs. in 0.025% concentra-
tion similarly caused no suppression, but
Smg/24 hrs. in the higher concentration did so.
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Fm. 6. Effects of 0.01% triamcinoloae acetonidc (TA) cream: 1 10 gm bid. (2 mg TA/24
hrs.); II 20 gm bi.d. (4 mg TA/24 hrs.); III 40 gm bid. (8 mg TA/24 hrs.). Effects of 1.0%
21-deoxy-triamcinoloae acctonidc (DTA) cream: 1 10 gm bid. (200 mg DTA/24 hrs.); 11
20 gm bi.d. (400 mg DTA/24 hrs.); III 40 gm bi.d. (800 mg DTA/24 hrs.). Effects of 1.0%
of the 9,ll-clichloro analog of triamcinolone acetonide cream, 10 gm bid. (200 mg of the
drug/24 hrs.).
bid L1
PLACEBO ICHLORISON[ (0.25% ) ( TA (0.025%)
2
0
46 4$ 50 52
352 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
PLASMA
CO RI ISOL
(pg /IOOmI)
URINARY
Ii — OHCS
mg / 24 Hr.)
URINARY
17 — 1(65
mg / 24 Hr.)
DAY
FIG. 7. Effects of a placebo (non-medicated) cream when 10 (1), 20 (II), and 49(111) gm
were applied bid. Effects of 025% dichlorisone acetate (DA) cream: I 10 gm ba.d. (50 mg
DA/24 hrs.) II 20 gm bid. (100 mg DA/24 hrs.); III 40 gm bid. (200 mg DA/24 hrs.).
Effects of 0.025% triamcinolone acetonide (TA) cream: I 8 gm b.i.d. (4 mg TA/24 hrs.); 11
16 gm bid. (8 mg TA/24 brs.).
DISCUSSION
In previous studies (2), we found that cer-
tain smaller doses of topical corticosteroids did
not suppress pituitary-adrenal function, even
when applied with occlusive dressings. This sug-
gested that dose-response curves with suppres-
sion as an end-point could be obtained and
would serve to compare the suppressing poten-
cies of different preparations. Suppression is
the first index of the systemic effect of exoge-
nous corticosteroids that occurs before the ap-
pearance of the metabolic responses to amounts
greater than those needed for replacement.
Studies involving percutaneous absorp-
tion of a drug are inherently more complex
than studies involving intravenous, intramus-
cular, or oral administration because numerous
variables affect absorption, such as the vehicle
in which the drug is applied, the concentration
of the drug in its vehicle, the condition of the
cpidermal barrier, and the presence or absence
of occlusion. The magnitude and duration of
the reactions seen may vary with the length of
time the drug is in contact with the skin and
the half-life of the drug in the body. These fac-
tors were kept as constant as possible in these
studies, except for concentration and for vari-
ables dependent upon the inherent properties
of the drugs, really the subject of the study.
Concentration was varied because we wished
to compare effects of commercial concentrations
of drugs. It is of particular interest that in
vitro evidence of the effect of concentration
upon absorption rate (13) was confirmed by
these in vivo studies, in which S mg of TA at
0.01% concentration did not cause suppression,
although the same amount of TA at 0.025%
concentration did produce suppression in the
same patient (J.V.C.). Despite the number of
variables involved, reproducibility of data in
different patients may be reasonably good, as
indicated by finding that suppressive doses of
0.025% TA were similar in patients J.V.C. and
E.H.
One difficulty in pursuing such studies is the
selection of dose ranges to give a dose-response
curve. Selection must obviously be empirical in
a previously unexplored area of investigation.
In exploring suitable dose ranges, we found
that very small amounts of some of these prep-
arations may cause suppression, such as 5 gm
twice daily of 0.05% fiurandrenolone or 0.5%
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prednisolone. Undoubtedly, dose-response re-
lationships could be derived for these drugs by
suitably decreasing the concentration or, per-
haps, the size of area of application.
Another observation of interest was that, in
at least some concentrations, the suppressing
percutaneous dose, e.g., somewhat less than 5 mg
of flurandrenolone/24 hours, 4 mg of fluoeino-
lone acetonide/24 hours, or 5—7.5 mg of TA/24
hrs., is quite close to the suppressing oral dose.
This suggests either that much more of the
applied amount is absorbed than previously
suspected, or that a given dose is more potent
when given percutaneously than when given
intermittently by the oral route. The latter
possibility seems more likely in view of Feld-
man and Maibaeh's finding that a maximum of
21.8% of an amount of hydroeortisone-C'4 ap-
plied to stripped, occluded skin can be recovered
in the urine (13). Percutaneous administration
may be analagous to continuous intravenous in-
fusion of a drug and little is known about rela-
tive intravenous and oral poteneies of steroids.
A possible source of error in studies of this
nature was suggested by the discovery of an
apparent reservoir of steroid in the skin after
the immediate period of application (15). If a
significant reservoir exists, the subsequent re-
use of a given area of skin several days after a
treatment period might give invalid data. In
several of our investigations (patients F.B.,
E.H., and J.V.C.; ref. 2) however, the reappli-
cation of occlusive dressings without medication
to recently treated areas produced no evidence
of systemic reactions from steroid remaining
in a reservoir. The usual prompt retum of
plasma and urine steroids to control levels
after a treatment period also suggests that
there are no appreciable lingering or cumulative
systemic reactions from steroid remaining in
the skin or elsewhere in the body.
Studies with occlusion alone are also per-
tinent in differentiating between the possible
effects of occlusion and the absorbed corticos-
teroid. When 20, 40, or 90% of body surface
was occluded, in previous (2) as well as present
studies, there were no changes in plasma and
urinary steroid levels or eosinophil counts ex-
cept for occasional elevation of these values.
Similarly, there were no changes in urinary
sodium or potassium excretion or in urinary
volume when 20 or 40% or body surface was
occluded. However, patient F.B.'s 24-hour
urinary volume was doubled when 90% of the
surface was occluded. Kirketerp (4) found that
diuresis occurred when he occluded areas ap-
parently greater than 50% of body surface.
Corresponding to his findings also, loss of body
weight was a constant finding in our patients.
This was most marked in patient R.R., who
lost 4 kg during a six-day treatment period.
This may have been due largely to excretion
of edema fluid that accompanied this patient's
inflammatory psoriasis. Some of the changes in
his urinary electrolyte content and volume may
have resulted from loss of edema fluid, and
occlusion of 90% of his body surface. It is
known that changes in extrarenal fluid loss
accompany healing of the skin in exfoliative
psoriasis (16), and could be reflected in the
alterations observed in this patient.
Regarding the relative potency of corticos-
teroids to suppress pituitary-adrenal function,
we can validly state a mg : mg potency ratio
only when the concentration of the drugs coni-
pared is identical and when they are applied
to areas of the same size. When 0.05% fluran-
drenolone and THTA were administered to pa-
tient F.B., the suppressing potency ratio of
flurandrenolone to THTA was greater than 12
to 1; suppression occurred with 5 mg/24 hours
of flurandrenolone and not with as much as
60 mg/24 hours of THTA. From the remainder
of that patient's study, we may conclude that
20 gm of 0.01% fluocinolonc acetonide twice
daily and 5 gm of 0.5% prednisolonc twice
daily suppress function more than 60 gm of
0.05% THTA twice daily.
From the study of patient E.H., it appears
that between 10 and 15 gm of 0.025% TA
twice daily is equivalent to between 45 and
90 gm of 0.05% THTA twice daily in its effect
on pituitary-adrenal function. Because THTA
was at the higher concentration, it is probably
also valid to state that the mg : mg potency
ratio is between 6:1 and 18:1. This study also
shows that 10—15 gm of 0.025% TA twice
daily arc more potent in suppressing effect than
20 gm of 0.25% dichlorisonc acetate twice
daily.
From the study of patient J.V.C., it is seen
that 10 gm of 1.0% of the 9,11-diehloro analog
of TA twice daily and between 8 and 16 gm of
0.025% TA twice daily have greater suppressing
potency than 40 gm of 0.01% TA, 0.25% di-
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ehiorisone acetate, or 1.0% 21-deoxy TA twice
daily.
Further exploration of doses between the
highest that does not cause suppression and
the lowest that does cause suppression would
be necessary for better resolution of the sup-
pression end-points. It is clear, however, that
0.05% THTA, 1.0% 21-deoxy TA, 0.25% di-
chlorisone acetate, and 0.01% TA are signifi-
cantly less potent in terms of pituitary-adrenal
suppression than 0.025% TA, 0.05% flurandren-
olone, 0.01% fluoeinolone aeetonide, or 0.5%
prednisolone.
One may also conclude from these studies
that at least 10 gm of 0.01% fluoeinolone
acetonide, S gm of 0.025% TA, and 40 gm of
0.01% TA may be applied twice daily with
occlusion to diseased skin over at least 20% of
the body surface without inducing systemic
sequelae. It also appears that 15 gm of 0.025%
TA applied only during the night lowers plasma
cortisol values in the morning just at the end
of the treatment period, although there is little
change in 24-hour urinary 17-OHCS levels;
this suggests that suppression by that dose is
very transient and that the adrenals recover
normal function during the ensuing daytime
hours. Twice that dose, however, is sufficient to
cause apparent 24-hour suppression. Further
studies of the effects of varying the treatment
schedule and of the effect of varying factors
that alter the rate of percutaneous absorption
might be of considerable practical and theoreti-
cal interest.
SUMMARY
Studies of systemic effects of percutaneously
absorbed corticosteroids are presented. The
relative potency, in terms of ability to suppress
pituitary-adrenal function, of several prepara-
tions is investigated. Several presently available
preparations are compared with four that
showed promise of having some separation of
anti-inflammatory activity from the less de-
sirable glueoeortieoid effects. The relative po-
teneies found, some of the factors affecting
results of studies of percutaneous absorption
in vivo, and non-suppressive doses of some
currently used cortieosteroid preparations
are discussed.
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DISCUSSION
Da. MAURAY J. Tyx, Haverhill, Mass.: We
are all very grateful to Dr. Seoggins for the
type of work he has been carrying on.
I may have missed it in the earlier part of
your discussion, but did you do any compara-
tive vaso-constrictivc assays or test the thera-
peutic effects with the concentrations of the
corticosteroids you refer to?
DR. RICHARD B. STOUOHTON, Cleveland,
Ohio: As usual Dr. Scoggins has made a very
good presentation of a great deal of work in a
very short period of time. I just wanted to ask
one question: of all the analogs that you tried,
it isn't quite clear from your data on a milli-
gram for milligram basis, were any of them as
potent as triamcinolone acetonide in suppressing
the adrenal gland?
Da. ROBERT B. Sc000INs (in closing): In
answer to Dr. Tyc's questions, evidence of
some separation of anti-inflammatory activity
from certain other glucocorticoid effects in
these drugs was obtained by other investigators
using several assay technics, primarily in experi-
mental animals. These are unpublished data,
except regarding dichlorisonc acetate, and must
of course be reported by those investigators
themselves. We have done no studies of vaso-
constrictive or therapeutic effect of these prep-
arations, so I cannot comment on their potential
clinical usefulness. Dr. Stoughton, we cannot
validly estimate a mg/mg potency ratio when
the concentrations in which drugs arc applied
are quite disparate, concentration being a prime
factor governing rate of percutaneous absorp-
tion. Lower concentrations of the 9, 1l-dichloro
analog of triamcinolonc acetonide, for example,
would have to be studied to obtain a better ap-
proximation of its suppression potency relative
to triamcinolonc acctonide.
